Scant Pipeline Competition For Roche’s Novel Flu Antiviral

 
• By Jo Shorthouse

With Priority Review given to Roche’s novel flu antiviral baloxavir marboxil for potential approval in the US, and Shionogi’s launch of the product under the brand name Xofluza, it looks set to lead the market for single-dose antivirals.

Virus
Baloxavir marboxil will fight both Influenza A and B infections

More from Anti-infective

More from Therapy Areas